Clinical trials: High Risk Cancer
Mammary Tumor, Nipple Discharge
A Novel Fluorescent Ductal Needle for Localization and Sampling of High-risk Breast Micro Lesions
This retrospective cohort study investigates the differences in the reliability of rapid pathology compared to postoperative pathology when utilizing a novel fluorescent localization needle equipped with a controllable shedding…
- Trial name
- NCT06994416
- Testing
- novel fluorescent localization marker needle, conventional localization marker needle
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The Fourth Affiliated Hospital of China Medical University
Prostate Cancer
A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer
The present study evaluates clinical outcomes and treatment-related toxicity following definitive ultra-high dose external beam radiotherapy delivered with two different regimens in patients with intermediate-risk adenocarcinoma…
- Trial name
- PROSINT (NCT04147806)
- Testing
- IGRT 45 Gy in 5 fractions of 9 Gy, IGRT 24 Gy single dose, Dexamethasone
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Albert Einstein College of Medicine
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
The purpose of this study is to determine the maximum tolerated dose (MTD) of ARGX-110 and/or the recommended Phase II dose (RP2D) in combination with a standard dose of azacytidine (AZA) in Phase 1; and to evaluate efficacy of…
- Trial name
- NCT03030612
- Testing
- ARGX-110, AZA
- Where
- 7 sites in France, Switzerland
- Volunteers
- 38 people
- Sponsor
- OncoVerity, Inc.
Breast Cancer
Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.
The purpose of the study is to to compare low dose of exemestane (babyexe) versus low dose of tamoxifen (babytam) in terms of change of quality of life from baseline to 12 months.
- Trial name
- BabyTears (NCT06364267)
- Testing
- Tamoxifen 10 MG, Exemestane 25 MG
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- Andrea DeCensi
Anterior Urethral Cancer, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
This study is about two chemotherapy study drug combinations (regimens) that are used for urothelial (bladder or upper urinary tract) cancer.
- Conditions
- Anterior Urethral Cancer, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Posterior Urethral Cancer, Recurrent Bladder Cancer
- Trial name
- NCT01639521
- Testing
- cisplatin, gemcitabine hydrochloride, methotrexate
- Sponsor
- University of Southern California
Basal Cell Carcinomas
Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
This study is a single site double blinded Phase II study to evaluate the chemopreventative effectiveness of vismodegib in the treatment of subjects at high risk for developing basal cell carcinomas (BCC).
- Trial name
- NCT02067104
- Testing
- Vismodegib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Arizona
Rheumatoid Arthritis, Ankylosing Spondylitis
PatientSpot Formerly Known as ArthritisPower
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout
- Trial name
- NCT03840928
- Where
- United States
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Global Healthy Living Foundation
Breast Cancer
Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients
The combination of taxanes, and especially docetaxel, with an anthracycline seems to be an important part of the chemotherapy regimens used in the adjuvant setting of patients with early-stage node-positive breast cancer…
- Trial name
- NCT00424606
- Testing
- Docetaxel, Epirubicin
- Where
- 12 sites in Greece
- Volunteers
- 658 people
- Sponsor
- Hellenic Oncology Research Group
Metastatic Melanoma
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving…
- Trial name
- NCT01993719
- Testing
- Aldesleukin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.
- Conditions
- Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma, Pancreatic Cancer
- Trial name
- PACT (NCT02791334)
- Testing
- LY3300054, Ramucirumab, Abemaciclib
- Where
- 14 sites in United States, Belgium and 5 more
- Volunteers
- 164 people
- Sponsor
- Eli Lilly and Company
Multiple Myeloma and Plasma Cell Neoplasm
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003399
- Testing
- carmustine, cisplatin, cyclophosphamide
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Acute Myeloid Leukemia (AML)
Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation
Patients with high risk AML non eligible for an intensive treatment and for an allogeneic transplantation will be treated with azacitidine and venetoclax.
- Trial name
- ILDA (NCT04886206)
- Testing
- DLI
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Nantes University Hospital
Hodgkin Lymphoma
Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma
The choice of a preferred first-line treatment requires balancing the desire for optimal disease control with the occurrence of early and late treatment-related effects.
- Trial name
- NCT01251107
- Testing
- Bleomycin, Etoposide, Doxorubicin
- Where
- Italy
- Volunteers
- 331 people
- Sponsor
- Fondazione Michelangelo
Breast Cancer, Chronic Myeloproliferative Disorders
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003107
- Testing
- recombinant interleukin-12
- Where
- United States
- Sponsor
- Indiana University
Urinary Bladder Neoplasms, Carcinoma, Transitional Cell
Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study
This open-label, randomised, multicentre, phase 2 study (OHAI-NMIBC-01) compares toripalimab plus sequential intravesical gemcitabine followed by mitomycin C (GEM→MMC) with toripalimab alone in adults with BCG-unresponsive or…
- Conditions
- Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder, Non-Muscle-Invasive Bladder Cancer
- Trial name
- OHAI-NMIBC-01 (NCT07189793)
- Testing
- Toripalimab, Gemcitabine (GEM), Mitomycin C (MMC)
- Where
- China
- Volunteers
- 106 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
High Grade Glioma
Predicting Sites of Tumour Progression in the Invasive Margin of Glioblastomas (PRaM-GBM Study)
Brain tumours are the leading cause of cancer deaths in children, men under the age of 45 and women under the age of 25. Glioblastoma is the most common and most malignant primary tumour.
- Trial name
- PRaM-GBM (NCT03294434)
- Testing
- Diffusion tensor Imaging (DTI)
- Where
- United Kingdom
- Volunteers
- 147 people
- Sponsor
- CCTU- Cancer Theme
Pediatric Acute Lymphoblastic Leukemia
Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia
Clinical and genetic factors consistent with High risk : Induction → Consolidation 1. BM MRD \< 0.01% : IM #1 → DI #1 → IM #2 → Maintenance 2. BM MRD ≥ 0.01% : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance 3.
- Trial name
- HR ALL (NCT06184009)
- Testing
- ALL, High risk
- Where
- 9 sites in South Korea
- Volunteers
- 370 people
- Sponsor
- Jae Wook Lee
Cholangiocarcinoma, Intrahepatic
Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence
The purpose of the study is to observe the effect of PD-1 Antibody（Tislelizumab） Combined With Capecitabine as Adjuvant Therapy to Prevent the Recurrence in High-risk Patients With Cholangiocarcinoma After Curative Resection.
- Trial name
- NCT04782804
- Testing
- Capecitabine, PD-1 Antibody（Tislelizumab）
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
This randomized phase III trial studies cytarabine and daunorubicin hydrochloride or idarubicin and cytarabine with or without vorinostat to see how well they work in treating younger patients with previously untreated acute…
- Trial name
- NCT01802333
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cytarabine, Daunorubicin Hydrochloride
- Where
- 447 sites in United States, Canada
- Volunteers
- 754 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma
Through the neoadjuvant treatment with a combination of Pucotenlimab and Lenvatinib, it eventually enables the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who have…
- Trial name
- NCT06129955
- Testing
- Pucotenlimab Combined With Lenvatinib
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.